| Literature DB >> 22458692 |
Simone Forterre1, Andreas Zurbriggen, David Spreng.
Abstract
BACKGROUND: There is increasing evidence suggesting that development of progressive canine cranial cruciate ligament (CCL) rupture involves a gradual degeneration of the CCL itself, initiated by a combination of factors, ranging from mechanical to biochemical. To date, knowledge is lacking to what extent cruciate disease results from abnormal biomechanics on a normal ligament or contrary how far preliminary alterations of the ligament due to biochemical factors provoke abnormal biomechanics. This study is focused on nitric oxide (NO), one of the potential biochemical factors. The NO-donor sodium nitroprusside (SNP) has been used to study NO-dependent cell death in canine cranial and caudal cruciate ligament cells and to characterize signaling mechanisms during NO-stimulation.Entities:
Mesh:
Substances:
Year: 2012 PMID: 22458692 PMCID: PMC3506925 DOI: 10.1186/1746-6148-8-40
Source DB: PubMed Journal: BMC Vet Res ISSN: 1746-6148 Impact factor: 2.741
Figure 1 Dose-dependent effect of SNP on cell viability in canine cruciate ligamentocytes. Cells were cultured with indicated concentrations of SNP (mM) for 18 h. Cell viability of CCL and □ CaCL cells was measured by MTT assay and calculated with the formula reported in the M&M section. Control cells were not treated with SNP. The graphs data represent the mean ± SD from at least three separate experiments of four different cell donors, each performed in triplicates. * P < 0.05, ** P < 0.01 CCL vs. CaCL at each indicated concentration.
Figure 2 Apoptotic fraction in canine cruciate ligament cells. Canine CCL and CaCL cells were stimulated with indicated concentrations of SNP for 18 h. Apoptotic cells were measured by FITC-annexinV/propidium iodide double stained flow cytometry. The stacked bar graphs are divided into two categories: patterned graphs indicate the early apoptotic fractions detected as cells stained annexin V positive and propidium iodide negative, plain-colored graphs indicate the end stage apoptosis and death detected as cells stained annexin V and propidium iodide positive. The graphs data represent the mean ± SD from at least three separate experiments of four different cell donors, each performed in triplicates. * P < 0.05, ** P < 0.01 for combined (early and late) apoptotic fractions of CCL or CaCL treated with SNP at each indicated concentration vs. control without SNP treatment.
Dose-dependent effect of SNP with/without inhibitors on bcl-2 protein level in canine CCL and CaCL cells
| bcl-2 [ng/mg protein] | ||
|---|---|---|
| | ||
| Control | 6.6 ± 0.3 | 7.0 ± 0.4 |
| SNP (0.3 mM) | 6.5 ± 0.1 | 5.1 ± 0.3* |
| SNP (0.5 mM) | 5.5 ± 0.3* | 4.9 ± 0.2* |
| SNP (1 mM) | 2.8 ± 0.2** | 3.9 ± 0.1** |
| SNP (0.5 mM) + Genistein (50 μM) | 8.8 ± 0.2†† | 10.9 ± 0.4†† |
| SNP (0.5 mM) + Uric acid (0.5 mM) | 7.8 ± 0.1†† | 7.9 ± 0.1†† |
| SNP (0.5 mM) + Taxifolin (50 μM) | 7.6 ± 0.3† | 6.7 ± 0.4† |
| SNP (0.5 mM) + PTIO (5 μM) | 5.8 ± 0.2 | 5.1 ± 0.2 |
Data represent the means and standard deviations from two separate experiments, n refers to the number of donors, and each performed in triplicates. Bcl-2 protein was measured by enzyme immunoassay. *, P < 0.05, **, P < 0.01 vs. control; †, P < 0.05, ††, P < 0.01 vs. SNP (0.5 mM); Dunnett`s multiple comparison test.
Figure 3 Time-dependent effect of SNP on canine cruciate ligamentocytes. The apoptotic cell number in canine CCL and □ CaCL cells was measured by flow cytometry. Cells were incubated in medium with 0.5 mM SNP for 6, 12, 18 and 24 h. Values correspond to the mean ± SD from at least three separate experiments of four different cell donors, each performed in triplicates. *, P < 0.05, **, P > 0.01 CCL vs. CaCL at each indicated time.
Cell viability of canine cruciate ligamentocytes in response to different inhibitors and SNP treatment
| Inhibitor pretreatment | CCL cell viability (n = 8) | CaCL cell viability (n = 8) | |||
|---|---|---|---|---|---|
| | | SNP treatment | SNP treatment | ||
| - | + | - | + | ||
| zVAD.fmk | 0 | 100 ± 6.0 | 75.5 ± 3.1 | 100 ± 5.9 | 73.6 ± 2.4 |
| | 100 μM | 92.5 ± 5.3 | 84.5 ± 4.3 | 92.2 ± 6.3 | 88.2 ± 3.6* |
| CalC | 0 | 100 ± 11.3 | 79.9 ± 5.3 | 100 ± 5.9 | 78.2 ± 7.2 |
| | 25 nM | 93.5 ± 6.9 | 73.4 ± 3.3 | 100 ± 6.0 | 68.7 ± 7.0 |
| PD98059 | 0 | 100 ± 5.6 | 75.8 ±6.4 | 100 ± 4.1 | 74.7 ± 9. 3 |
| | 10 μM | 81.2 ± 7.2* | 61.8 ± 3.1* | 78.3 ± 7.2* | 52.2 ± 9.2* |
| SB202190 | 0 | 100 ±11.3 | 73.4 ± 5.4 | 100 ± 6.0 | 74.2 ± 7.7 |
| | 10 μM | 74.2 ±2.1* | 65.9 ± 4.5 | 75.2 ± 5.8* | 79.8 ± 2.4 |
| Genistein | 0 | 100 ± 6.0 | 69.6 ± 6.1 | 100 ± 5.8 | 72.3 ± 5.7 |
| | 50 μM | 101 ± 6.4 | 97.4 ±9.3** | 106.1 ±6.3 | 101.9 ± 2.5** |
| NS-398 | 0 | 100 ± 5.4 | 64.9 ± 3.6 | 100 ± 5.4 | 63.2 ± 4.1 |
| | 50 μM | 89.5 ± 17.7 | 78.1 ± 3.9* | 88.5 ± 4.7* | 88.8 ± 2.5** |
| | 100 μM | 74.7 ± 14.4 | 75.3 ± 4.2* | 81.8 ± 12.1 | 92.4 ± 2.7** |
| SN-50 | 0 | 100 ± 8.3 | 74.6 ± 3.8 | 100 ± 8.4 | 81.2 ± 2.4 |
| | 50 μM | 97.3 ± 8.6 | 64.4 ± 12.6 | 101.4 ± 4.5 | 67.3 ± 2.7* |
| PDTC | 0 | 100 ± 8.3 | 74.6 ± 3.8 | 100 ± 8.4 | 81.2 ± 2.4 |
| | 10 μM | 42.7 ± 7.7** | 5.5 ± 1.9** | 43.8 ± 2.3** | 2.1 ± 1.7** |
| Uric acid | 0 | 100 ± 9.2 | 73.5 ± 5.4 | 100 ± 5.6 | 78.2 ± 2.4 |
| | 0.5 mM | 103.6 ± 9.5 | 102.7 ± 12.1* | 101.9 ± 6.2 | 94.6 ± 5.9* |
| PTIO | 0 | 100 ± 6.2 | 64.9 ± 2.6 | 100 ± 9.3 | 61.2 ± 4.6 |
| | 5 μM | 87.9 ± 7.3 | 80.9 ± 1.5* | 96.2 ± 9.6 | 73.8 ± 3.2* |
| Taxifolin | 0 | 100 ± 3.7 | 76.2 ± 4.2 | 100 ± 5.6 | 74.3 ± 7.7 |
| 100 μM | 91.6 ± 11.5 | 84.8 ± 10.6 | 101.3 ± 4.1 | 97.3 ± 6.8* | |
Values correspond to the mean ± SD, calculated by using the formula from M&M section of three separate experiments of n different cell donors, each performed in triplicates. Cruciate ligamentocytes were preincubated with the indicated concentrations of the inhibitors for 2 h. SNP or none SNP were then added to the cultures and allowed to incubate for an additional 18-h period. SNP concentrations used were 0.2 to 0.25 mM. Cell viability was assayed by MTT assay. P-values indicate difference within the same type of cell and SNP treatment versus absent inhibitor: *, P < 0.05; **, P < 0.01.
Dose-dependent effect of SNP and inhibitors on PGE production in canine CCL and CaCL cells
| | |||
|---|---|---|---|
| Control | 35.4 ± 0.1 | 29.0 ± 0.6 | 620 ± 10 |
| SNP (0.2 mM) | 90.1 ± 1.3* | 81.8 ± 2.2* | 995 ± 30* |
| SNP (0.4 mM) | 134.2 ± 5.4* | 91.6 ± 14.5* | |
| SNP (0.5 mM) | 247.2 ± 16.9* | 108.6 ± 10.6* | 1636 ± 22* |
| SNP (1.0 mM) | 239.4 ± 12.6* | 179.8 ± 8.2* | 12790 ± 870* |
| SNP (0.2 mM) + Genistein (50 μM) | 39.5 ± 3.4† | 43.1 ± 2.3† | |
| SNP (0.2 mM) + NS-398 (50 μM) | 46.2 ± 2.1† | 46.3 ± 3.8† | |
Data are the mean ± SD from two separate experiments each performed in triplicates. PGE2 release in pg of 2 × 106 cells into 1 mL medium was measured by enzyme immunoassay. Human chondrocytes served as positive controls. *, P < 0.01 vs. control; †, P < 0.01 vs. SNP (0.2 mM); Dunnett`s multiple comparison test.